MA59373B1 - [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2 - Google Patents
[1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2Info
- Publication number
- MA59373B1 MA59373B1 MA59373A MA59373A MA59373B1 MA 59373 B1 MA59373 B1 MA 59373B1 MA 59373 A MA59373 A MA 59373A MA 59373 A MA59373 A MA 59373A MA 59373 B1 MA59373 B1 MA 59373B1
- Authority
- MA
- Morocco
- Prior art keywords
- diazino
- pyrimidines
- her2 inhibitors
- her2
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des nouvelles [1,3]diazino[5,4-d]pyrimidines et des dérivés de formule (I), dans laquelle les groupes R1, R2, R3 et R4 ont les significations indiquées dans les revendications et la description, leur utilisation en tant qu'inhibiteurs de HER2 et leurs mutants, des compositions pharmaceutiques qui contiennent lesdits composés et leur utilisation en tant que médicaments, en particulier en tant qu'agents pour le traitement et/ou la prévention de maladies oncologiques.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20171221 | 2020-04-24 | ||
| EP21716218.9A EP4139309B9 (fr) | 2020-04-24 | 2021-04-07 | [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2 |
| PCT/EP2021/059015 WO2021213800A1 (fr) | 2020-04-24 | 2021-04-07 | [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA59373B1 true MA59373B1 (fr) | 2025-02-28 |
Family
ID=70470818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA59373A MA59373B1 (fr) | 2020-04-24 | 2021-04-07 | [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2 |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US11608343B2 (fr) |
| EP (2) | EP4139309B9 (fr) |
| JP (2) | JP7260723B2 (fr) |
| KR (2) | KR20250016507A (fr) |
| CN (13) | CN118307543A (fr) |
| AR (1) | AR121779A1 (fr) |
| AU (1) | AU2021260721A1 (fr) |
| BR (1) | BR112022021514A2 (fr) |
| CA (1) | CA3173602A1 (fr) |
| CL (1) | CL2022002579A1 (fr) |
| CO (1) | CO2022015054A2 (fr) |
| CR (1) | CR20220537A (fr) |
| DK (1) | DK4139309T5 (fr) |
| DO (1) | DOP2022000189A (fr) |
| EC (1) | ECSP22072777A (fr) |
| ES (1) | ES3013860T3 (fr) |
| FI (1) | FI4139309T3 (fr) |
| HR (1) | HRP20250426T1 (fr) |
| HU (1) | HUE070805T2 (fr) |
| IL (2) | IL320477A (fr) |
| JO (1) | JOP20220271A1 (fr) |
| LT (1) | LT4139309T (fr) |
| MA (1) | MA59373B1 (fr) |
| MX (1) | MX2022013223A (fr) |
| PE (1) | PE20230827A1 (fr) |
| PH (1) | PH12022552745A1 (fr) |
| PL (1) | PL4139309T3 (fr) |
| PT (1) | PT4139309T (fr) |
| RS (1) | RS66557B1 (fr) |
| SI (1) | SI4139309T1 (fr) |
| SM (1) | SMT202500164T1 (fr) |
| UA (1) | UA130588C2 (fr) |
| WO (1) | WO2021213800A1 (fr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| EP4100409B1 (fr) * | 2020-02-03 | 2024-08-28 | Boehringer Ingelheim International GmbH | [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2 |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| WO2022266458A1 (fr) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | Dérivés de 6-hétérocycloalkyle-quinazoline et leurs utilisations |
| CR20230604A (es) | 2021-06-26 | 2024-02-19 | Array Biopharma Inc | Inhibidores de mutación de her2 |
| WO2023154124A1 (fr) * | 2022-02-09 | 2023-08-17 | Enliven Therapeutics, Inc. | Dérivés de quinazoline hétérocycliques acylés utilisés en tant qu'inhibiteurs de erbb2 |
| CN118715216A (zh) | 2022-03-28 | 2024-09-27 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| CA3267358A1 (fr) * | 2022-04-05 | 2025-03-22 | Voronoi Inc. | Dérivé hétéroaryle et son utilisation |
| CN117384162A (zh) * | 2022-05-17 | 2024-01-12 | 浙江文达医药科技有限公司 | 选择性her2抑制剂 |
| WO2024027695A1 (fr) * | 2022-08-04 | 2024-02-08 | 微境生物医药科技(上海)有限公司 | Composés utiles comme inhibiteurs de her2 |
| US20240132521A1 (en) | 2022-08-22 | 2024-04-25 | Iambic Therapeutics, Inc. | Compounds and methods for modulating her2 |
| EP4637772A1 (fr) | 2022-12-22 | 2025-10-29 | Boehringer Ingelheim International GmbH | Programme de dosage d'une dispersion solide d'un inhibiteur de her2 |
| AU2023410266A1 (en) | 2022-12-22 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Solid dispersion of a her2 inhibitor |
| AU2023410324A1 (en) | 2022-12-22 | 2025-05-15 | Boehringer Ingelheim International Gmbh | Crystalline forms of a her2 inhibitor |
| WO2024200637A2 (fr) | 2023-03-29 | 2024-10-03 | Boehringer Ingelheim International Gmbh | Schéma posologique d'un inhibiteur d'her2 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| EP4720678A1 (fr) | 2023-05-31 | 2026-04-08 | Boehringer Ingelheim International GmbH | Survivine en tant que biomarqueur pour prédire la réactivité d'un traitement du cancer |
| CN116903615A (zh) * | 2023-06-21 | 2023-10-20 | 江苏丽源医药有限公司 | 一种妥卡替尼及其中间体的制备方法 |
| CN121568696A (zh) | 2023-07-28 | 2026-02-24 | 勃林格殷格翰国际有限公司 | 制备her2抑制剂的方法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN121729231A (zh) * | 2023-09-06 | 2026-03-24 | 勃林格殷格翰国际有限公司 | 用HER2抑制剂和CYP3A和/或P-gp调节剂进行的癌症治疗 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| US20250228858A1 (en) | 2023-12-20 | 2025-07-17 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| US20250205238A1 (en) | 2023-12-20 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| WO2025171296A1 (fr) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025210042A1 (fr) * | 2024-04-03 | 2025-10-09 | Boehringer Ingelheim International Gmbh | Combinaison de zongertinib avec un inhibiteur de sos1 destiné à être utilisé dans le traitement du cancer |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (fr) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras |
| US20250376476A1 (en) | 2024-06-11 | 2025-12-11 | Boehringer Ingelheim International Gmbh | Crystalline forms of a HER2 tyrosine kinase inhibitor |
| WO2025265060A1 (fr) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Compositions thérapeutiques et procédés de gestion d'effets liés au traitement |
| WO2026006747A1 (fr) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| CN121270563A (zh) * | 2024-07-01 | 2026-01-06 | 北京鞍石生物科技股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2026015790A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015796A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015825A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas |
| WO2026015801A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble liés à ras |
| WO2026027757A1 (fr) | 2024-08-02 | 2026-02-05 | Boehringer Ingelheim International Gmbh | Traitement du cancer avec métastases dans le système nerveux central |
| WO2026050446A1 (fr) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026072904A2 (fr) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions et méthodes de traitement du cancer du poumon |
| WO2026077844A1 (fr) | 2024-10-07 | 2026-04-16 | Boehringer Ingelheim International Gmbh | Dispersions solides ayant des particules d'émulsion stabilisées |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW414798B (en) * | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| AP2004003058A0 (en) | 2001-12-12 | 2004-06-30 | Pfizer Prod Inc | Quinazoline derivatives for the treatment of abnormal cell growth. |
| JP2007510708A (ja) | 2003-11-06 | 2007-04-26 | ファイザー・プロダクツ・インク | 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ |
| ATE446294T1 (de) | 2005-11-15 | 2009-11-15 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| US20070107957A1 (en) * | 2005-11-16 | 2007-05-17 | Lonnie Lehrer | Automobile propulsion system |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| EP3778584A1 (fr) | 2014-06-19 | 2021-02-17 | ARIAD Pharmaceuticals, Inc. | Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines |
| EP3294712A4 (fr) | 2015-05-13 | 2018-11-07 | ARIAD Pharmaceuticals, Inc. | Composés hétéroaryle d'inhibition de la kinase |
| CN111032655B (zh) | 2017-08-31 | 2022-09-02 | 达纳-法伯癌症研究所股份有限公司 | Egfr和/或her2抑制剂和使用方法 |
| JP7333313B2 (ja) | 2017-09-01 | 2023-08-24 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 窒素含有複素環化合物、製造方法、中間体、組成物および使用 |
| EP4100409B1 (fr) | 2020-02-03 | 2024-08-28 | Boehringer Ingelheim International GmbH | [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2 |
| JP7626774B2 (ja) | 2020-02-03 | 2025-02-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| WO2021231400A1 (fr) * | 2020-05-12 | 2021-11-18 | Accutar Biotechnology, Inc. | Bis-aryl éthers contenant de la n-acyl azétidine en tant qu'inhibiteurs de l'egfr/her2 |
-
2021
- 2021-04-06 US US17/223,132 patent/US11608343B2/en active Active
- 2021-04-07 CN CN202410475947.1A patent/CN118307543A/zh active Pending
- 2021-04-07 KR KR1020257002191A patent/KR20250016507A/ko active Pending
- 2021-04-07 CN CN202410490491.6A patent/CN118388490A/zh active Pending
- 2021-04-07 WO PCT/EP2021/059015 patent/WO2021213800A1/fr not_active Ceased
- 2021-04-07 EP EP21716218.9A patent/EP4139309B9/fr active Active
- 2021-04-07 CN CN202410479057.8A patent/CN118388487A/zh active Pending
- 2021-04-07 DK DK21716218.9T patent/DK4139309T5/da active
- 2021-04-07 IL IL320477A patent/IL320477A/en unknown
- 2021-04-07 CN CN202410481750.9A patent/CN118388488A/zh active Pending
- 2021-04-07 CN CN202410508211.XA patent/CN118388495A/zh active Pending
- 2021-04-07 HR HRP20250426TT patent/HRP20250426T1/hr unknown
- 2021-04-07 KR KR1020227040861A patent/KR102759974B1/ko active Active
- 2021-04-07 UA UAA202204335A patent/UA130588C2/uk unknown
- 2021-04-07 MX MX2022013223A patent/MX2022013223A/es unknown
- 2021-04-07 CN CN202410475949.0A patent/CN118307544A/zh active Pending
- 2021-04-07 PT PT217162189T patent/PT4139309T/pt unknown
- 2021-04-07 MA MA59373A patent/MA59373B1/fr unknown
- 2021-04-07 JP JP2022563041A patent/JP7260723B2/ja active Active
- 2021-04-07 CN CN202180030549.3A patent/CN115485277B/zh active Active
- 2021-04-07 CN CN202410490516.2A patent/CN118388491A/zh active Pending
- 2021-04-07 PE PE2022002443A patent/PE20230827A1/es unknown
- 2021-04-07 LT LTEPPCT/EP2021/059015T patent/LT4139309T/lt unknown
- 2021-04-07 RS RS20250199A patent/RS66557B1/sr unknown
- 2021-04-07 BR BR112022021514A patent/BR112022021514A2/pt active IP Right Grant
- 2021-04-07 CN CN202410494941.9A patent/CN118388492A/zh active Pending
- 2021-04-07 CN CN202410494942.3A patent/CN118388493A/zh active Pending
- 2021-04-07 FI FIEP21716218.9T patent/FI4139309T3/fi active
- 2021-04-07 EP EP24221865.9A patent/EP4566611A3/fr active Pending
- 2021-04-07 CN CN202410479058.2A patent/CN118619956A/zh active Pending
- 2021-04-07 PL PL21716218.9T patent/PL4139309T3/pl unknown
- 2021-04-07 SM SM20250164T patent/SMT202500164T1/it unknown
- 2021-04-07 AR ARP210100910A patent/AR121779A1/es unknown
- 2021-04-07 CN CN202410508210.5A patent/CN118388494A/zh active Pending
- 2021-04-07 HU HUE21716218A patent/HUE070805T2/hu unknown
- 2021-04-07 SI SI202130269T patent/SI4139309T1/sl unknown
- 2021-04-07 CN CN202410481753.2A patent/CN118388489A/zh active Pending
- 2021-04-07 ES ES21716218T patent/ES3013860T3/es active Active
- 2021-04-07 PH PH1/2022/552745A patent/PH12022552745A1/en unknown
- 2021-04-07 IL IL297490A patent/IL297490B2/en unknown
- 2021-04-07 AU AU2021260721A patent/AU2021260721A1/en active Pending
- 2021-04-07 CA CA3173602A patent/CA3173602A1/fr active Pending
- 2021-04-07 CR CR20220537A patent/CR20220537A/es unknown
- 2021-10-28 JO JOJO/P/2022/0271A patent/JOP20220271A1/ar unknown
-
2022
- 2022-09-14 DO DO2022000189A patent/DOP2022000189A/es unknown
- 2022-09-21 EC ECSENADI202272777A patent/ECSP22072777A/es unknown
- 2022-09-23 CL CL2022002579A patent/CL2022002579A1/es unknown
- 2022-10-21 CO CONC2022/0015054A patent/CO2022015054A2/es unknown
-
2023
- 2023-02-10 US US18/167,168 patent/US20230374021A1/en not_active Abandoned
- 2023-04-06 JP JP2023062141A patent/JP2023085489A/ja active Pending
-
2024
- 2024-06-25 US US18/753,429 patent/US20250122204A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA59373B1 (fr) | [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2 | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| JOP20240165A1 (ar) | مشتقات بيبريدينيل سبيرو سيكليك كمثبطات عامل مكمل b واستخداماتها | |
| CY1111086T1 (el) | Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace) | |
| MA45222B1 (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| PH12021552760A1 (en) | 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2 | |
| DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| CY1111070T1 (el) | Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace) | |
| GEAP202316387A (en) | Phosphorus derivatives as novel sos1 inhibitors | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
| ATE372995T1 (de) | Benzo(b)(1,4)dioxepinderivate | |
| SA522431498B1 (ar) | مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا | |
| MX2022008627A (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas. | |
| WO2020247298A3 (fr) | Dérivés d'indazole 5 -, 6-disubstitués, 1-pyrazolyle, en tant qu'inhibiteurs de lrrk2, compositions pharmaceutiques et utilisations correspondantes | |
| DE602007001463D1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| EA201992090A1 (ru) | ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| MX2023011829A (es) | Derivados de uracilo como inhibidores de trpa1. | |
| MX2023003516A (es) | Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7). | |
| ATE368040T1 (de) | Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren | |
| MX2024011755A (es) | Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2) | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados |